Tagitanlimab

DB18221InvestigationalProtein Based Therapies

Tagitanlimab: Overview.

Mechanism: Pharmacologically active on Programmed cell death 1 ligand 1
Curator reviewed
Also known as: Immunoglobulin g1 (237-alanine,238-alanine,240-alanine), anti-(human programmed death-ligand 1) (human monoclonal kla167 .gamma.1-chain), disulfide with human monoclonal kla167 .kappa.-chain, dimer
Code names: HBM-9167 · KL-A167

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tagitanlimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.